Scarica l'app Stockscreener
1.79
0.00%
0.00
Dopo l'orario di chiusura:
1.77
-0.02
-1.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.79
Aprire:
$1.75
Volume 24 ore:
4.97M
Relative Volume:
0.64
Capitalizzazione di mercato:
$586.94M
Reddito:
$4.41M
Utile/perdita netta:
$-67.85M
Rapporto P/E:
-7.9274
EPS:
-0.2258
Flusso di cassa netto:
$-57.15M
1 W Prestazione:
-8.67%
1M Prestazione:
-7.73%
6M Prestazione:
+1.13%
1 anno Prestazione:
+159.80%
Intervallo 1D:
$1.72
$1.81
Intervallo di 1 settimana:
$1.72
$1.96
Portata 52W:
$0.57
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Nome
Ocugen Inc
Settore
Industria
Telefono
484-328-4701
Indirizzo
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.79 | 586.94M | 4.41M | -67.85M | -57.15M | -0.2258 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Iniziato | Canaccord Genuity | Buy |
| 2026-03-11 | Iniziato | Oppenheimer | Outperform |
| 2024-10-15 | Iniziato | Maxim Group | Buy |
| 2023-03-01 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Iniziato | Mizuho | Buy |
| 2022-06-15 | Ripresa | ROTH Capital | Buy |
| 2022-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Iniziato | Noble Capital Markets | Outperform |
| 2021-06-11 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
Mostra tutto
Ocugen Inc Borsa (OCGN) Ultime notizie
Evaluating Ocugen (OCGN) After Recent Share Price Swings And Gene Therapy Progress - finance.yahoo.com
Ocugen, Inc. (OCGN.MX) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Wall Street Zen Downgrades Ocugen (NASDAQ:OCGN) to Sell - MarketBeat
Earnings call transcript: Ocugen Q4 2025 reveals steady R&D investment By Investing.com - Investing.com
Ocugen (OCGN) has a healthy cash position for 2026 - MSN
Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue? - finance.yahoo.com
Hennion & Walsh Asset Management Inc. Invests $1.36 Million in Ocugen, Inc. $OCGN - MarketBeat
Ocugen files petition in Delaware court to validate share increase amendment - Investing.com
Director Zhang Junge exercises 194,134 Ocugen (OCGN) options, lifts direct stake to 1.36M shares - Stock Titan
Ocugen falls after 12-month data from mid-stage trial for GA therapy - MSN
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study - The Globe and Mail
OCGN Finishes Initial Participant Registration for Key Stargardt Disease Trial - Bitget
OCGN Stock Price, Quote & Chart | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Ocugen Hits Key Milestone In GARDian3 Stargardt Gene Therapy Program - Sahm
Ocugen Achieves Key Enrollment Target in Stargardt Disease Gene Therapy Trial - AD HOC NEWS
Ocugen completes enrollment in Stargardt disease gene therapy trial By Investing.com - Investing.com Australia
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
$Ocugen (OCGN.US)$ - Moomoo
Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | Ocugen, Inc. - Ocugen, Inc.
Ocugen completes dosing early in phase 2/3 GARDian3 trial for Stargardt disease - Ophthalmology Times
Ocugen (OCGN) Completes Dosing in Key Clinical Trial for Stargar - GuruFocus
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of Ocu410st for Stargardt Disease - marketscreener.com
Ocugen completes enrollment in Stargardt disease gene therapy trial - Investing.com
Ocugen wraps 63-patient Stargardt gene therapy dosing in 9 months - Stock Titan
Block Trades: What is the next catalyst for Ocugen IncEarnings Recap Report & Real-Time Market Trend Scan - baoquankhu1.vn
Ocugen, Inc. targets 100s of mutations with gene therapies to address 132 billion dollar vision loss burden - Traders Union
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
OCGN PE Ratio & Valuation, Is OCGN Overvalued - Intellectia AI
Ocugen (OCGN) Reveals OCU410 Clinical Trial Data - insidermonkey.com
Ocugen, Inc. (NASDAQ:OCGN) Q3 2025 Earnings Call Transcript - MSN
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Retinal specialists drive clinical progress on modifier gene therapy, Ocugen, Inc. asserts - Traders Union
OCGN stock tanks after gene therapy trial update — what did Ocugen announce? - MSN
Ocugen (OCGN) price target increased by 11.11% to 10.20 - MSN
Ocugen Inc. (OCGN): One of the popular penny stocks on Robinhood - MSN
Risk Recap: Is Ocugen Inc undervalued by DCF analysisMarket Risk Summary & Weekly Return Optimization Alerts - baoquankhu1.vn
How The Ocugen (OCGN) Narrative Is Shifting With Retinal Gene Therapy Data And New Valuations - Yahoo Finance
Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences - MSN
Ocugen Inc. (OCGN): One of the Popular Penny Stocks on Robinhood - Insider Monkey
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Vanguard (OCGN) disaggregates holdings; reports 0% ownership in Ocugen - Stock Titan
Can Ocugen succeed where other gene therapy makers have struggled? - Pharma Voice
Ocugen Updates Roadmap for Gene-Agnostic Retinal Therapies - TipRanks
What is Noble Financial's Estimate for Ocugen Q3 Earnings? - MarketBeat
HC Wainwright Issues Positive Forecast for Ocugen Earnings - MarketBeat
Ocugen posts investor presentation outlining progress across three gene-therapy BLAs, Phase 3 enrollment and positive Phase 2/3 data - TradingView
Ocugen (OCGN) showcases retinal gene therapy pipeline with new OCU410 Phase 2 data - Stock Titan
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen appoints Rita Johnson-Greene as chief financial officer - MSN
Ocugen (NASDAQ:OCGN) Given "Buy" Rating at Chardan Capital - MarketBeat
Ocugen (OCGN) Stock Maintained at Buy Rating by Chardan Capital - GuruFocus
Ocugen Inc Azioni (OCGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):